Compare Stocks: ADMA, ACAD, ALLO, and SYRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.43 -3.7%	$27.67	$19.69 ▼ $30.96	$4.55B	0.86	1.47 million shs	1.31 million shs
ADMA ADMA Biologics	$9.70 -1.1%	$9.26	$7.21 ▼ $20.46	$2.20B	0.78	2.55 million shs	2.60 million shs
ALLO Allogene Therapeutics	$1.67 -2.3%	$1.91	$1.04 ▼ $4.46	$590.79M	0.47	5.25 million shs	5.91 million shs
SYRE Spyre Therapeutics	$88.17 -4.1%	$97.32	$15.49 ▼ $110.18	$8.09B	2.99	1.34 million shs	918,763 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.04%	-1.31%	-10.47%	+13.06%	+7.66%
ADMA ADMA Biologics	+3.15%	+13.94%	-0.30%	+12.76%	-38.80%
ALLO Allogene Therapeutics	+1.18%	-0.58%	-18.18%	-16.59%	+46.15%
SYRE Spyre Therapeutics	-0.07%	+1.12%	-13.64%	+6.64%	+501.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.43 -3.7%	$27.67	$19.69 ▼ $30.96	$4.55B	0.86	1.47 million shs	1.31 million shs
ADMA ADMA Biologics	$9.70 -1.1%	$9.26	$7.21 ▼ $20.46	$2.20B	0.78	2.55 million shs	2.60 million shs
ALLO Allogene Therapeutics	$1.67 -2.3%	$1.91	$1.04 ▼ $4.46	$590.79M	0.47	5.25 million shs	5.91 million shs
SYRE Spyre Therapeutics	$88.17 -4.1%	$97.32	$15.49 ▼ $110.18	$8.09B	2.99	1.34 million shs	918,763 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.04%	-1.31%	-10.47%	+13.06%	+7.66%
ADMA ADMA Biologics	+3.15%	+13.94%	-0.30%	+12.76%	-38.80%
ALLO Allogene Therapeutics	+1.18%	-0.58%	-18.18%	-16.59%	+46.15%
SYRE Spyre Therapeutics	-0.07%	+1.12%	-13.64%	+6.64%	+501.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$34.36	35.12% Upside
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	92.44% Upside
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.30	397.01% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$109.69	24.41% Upside

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, ALLO, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/14/2026	ADMA ADMA Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/9/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/9/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$123.00
9/8/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$121.00
9/2/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/1/2026	SYRE Spyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	SYRE Spyre Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$135.00 ➝ $127.00
8/26/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$130.00 ➝ $123.00
8/26/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$132.00 ➝ $121.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.09	$0.85 per share	29.77	$7.25 per share	3.51
ADMA ADMA Biologics	$510.17M	4.26	$0.65 per share	15.00	$2.01 per share	4.83
ALLO Allogene Therapeutics	$20K	28,848.42	N/A	N/A	$1.30 per share	1.28
SYRE Spyre Therapeutics	$890K	8,711.99	N/A	N/A	$7.21 per share	12.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	11.45	25.95	N/A	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
ADMA ADMA Biologics	$146.93M	$0.70	13.86	11.41	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
ALLO Allogene Therapeutics	-$190.89M	-$0.67	N/A	N/A	N/A	N/A	-50.04%	-36.74%	11/5/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest ADMA, ACAD, ALLO, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	-$0.13	+$0.0414	-$0.13	$0.00 million	$4.64 million
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
ADMA ADMA Biologics	0.49	6.97	3.81
ALLO Allogene Therapeutics	N/A	10.72	10.72
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ADMA ADMA Biologics	75.68%
ALLO Allogene Therapeutics	83.63%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
ADMA ADMA Biologics	3.90%
ALLO Allogene Therapeutics	13.20%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	798	172.31 million	127.16 million	Optionable
ADMA ADMA Biologics	647	223.99 million	215.25 million	Optionable
ALLO Allogene Therapeutics	152	345.49 million	299.89 million	Optionable
SYRE Spyre Therapeutics	112	87.94 million	74.14 million	Optionable

ADMA, ACAD, ALLO, and SYRE Headlines

Recent News About These Companies

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Moderate Buy" by Brokerages

September 20 at 3:15 AM | americanbankingnews.com

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

September 17, 2026 | finance.yahoo.com

Financial Contrast: Spyre Therapeutics (NASDAQ:SYRE) vs. Genmab A/S (NASDAQ:GMAB)

September 17, 2026 | americanbankingnews.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Moderate Buy" from Analysts

September 15, 2026 | marketbeat.com

California State Teachers Retirement System Increases Stake in Spyre Therapeutics, Inc. $SYRE

September 15, 2026 | marketbeat.com

Engineers Gate Manager LP Takes $3.42 Million Position in Spyre Therapeutics, Inc. $SYRE

September 14, 2026 | marketbeat.com

11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

September 14, 2026 | marketbeat.com

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

September 10, 2026 | insidermonkey.com

Squarepoint Ops LLC Invests $12.39 Million in Spyre Therapeutics, Inc. $SYRE

September 10, 2026 | marketbeat.com

Allianz Asset Management GmbH Takes Position in Spyre Therapeutics, Inc. $SYRE

September 10, 2026 | marketbeat.com

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results

September 9, 2026 | blockonomi.com

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

September 9, 2026 | zacks.com

Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)

September 9, 2026 | marketbeat.com

Maven Securities LTD Invests $3.55 Million in Spyre Therapeutics, Inc. $SYRE

September 9, 2026 | marketbeat.com

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD ...

September 8, 2026 | markets.businessinsider.com

Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis

September 8, 2026 | rttnews.com

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

September 8, 2026 | finance.yahoo.com

Spyre Therapeutics' (SYRE) Buy Rating Reiterated at BTIG Research

September 8, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down - Here's What Happened

September 8, 2026 | marketbeat.com

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

September 8, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA, ACAD, ALLO, and SYRE Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.43 -0.98 (-3.71%)

Closing price 04:00 PM Eastern

Extended Trading

$25.49 +0.06 (+0.24%)

As of 07:30 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ADMA Biologics NASDAQ:ADMA

$9.70 -0.11 (-1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$9.65 -0.05 (-0.52%)

As of 07:54 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Allogene Therapeutics NASDAQ:ALLO

$1.67 -0.04 (-2.34%)

Closing price 04:00 PM Eastern

Extended Trading

$1.69 +0.02 (+1.02%)

As of 07:55 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Spyre Therapeutics NASDAQ:SYRE

$88.17 -3.80 (-4.13%)

Closing price 04:00 PM Eastern

Extended Trading

$87.15 -1.02 (-1.16%)

As of 07:30 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, ALLO, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADMA, ACAD, ALLO, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADMA, ACAD, ALLO, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA, ACAD, ALLO, and SYRE Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

ADMA Biologics NASDAQ:ADMA

Allogene Therapeutics NASDAQ:ALLO

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, ALLO, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADMA, ACAD, ALLO, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADMA, ACAD, ALLO, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA, ACAD, ALLO, and SYRE Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

ADMA Biologics NASDAQ:ADMA

Allogene Therapeutics NASDAQ:ALLO

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools